Tybourne Capital Management (Hk) LTD Zentalis Pharmaceuticals, Inc. Transaction History
Tybourne Capital Management (Hk) LTD
- $34.5 Billion
- Q2 2025
A detailed history of Tybourne Capital Management (Hk) LTD transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Tybourne Capital Management (Hk) LTD holds 1,478,152 shares of ZNTL stock, worth $2.13 Million. This represents 4.96% of its overall portfolio holdings.
Number of Shares
1,478,152
Previous 961,486
53.74%
Holding current value
$2.13 Million
Previous $1.53 Billion
12.16%
% of portfolio
4.96%
Previous 6.49%
Shares
8 transactions
Others Institutions Holding ZNTL
# of Institutions
138Shares Held
60.8MCall Options Held
7.9KPut Options Held
42.5K-
Matrix Capital Management Company, LP Waltham, MA14MShares$20.1 Million6.94% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.94 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.07MShares$4.42 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$4.15 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.8MShares$4.03 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $82.1M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...